Lewati ke konten
Info
Flow
Beranda
Pasar
Berita
Square
InfoAI
Cari pasar, berita, atau tanya InfoAI
⌘K
Masuk
Beranda
Berita
Pasar
Square
Akun
FDA approves Retatrutide this year? | Yes / No 2,7% | InfoFlow
F
Tekno
FDA approves Retatrutide this year?
2,7
%
Peluang pasar
▼0,1pp
24h
Vol
$595 rb
Diselesaikan 1 Jan
1H
6H
1D
1W
1M
SEMUA
Buku order
Yes
No
Harga
Ukuran
Total
Tengah
—
Aturan penyelesaian
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee…
Perluas
▾
Pemegang
0
Aktivitas
0
Komentar
0
